GSK PLC GSK StarRatingValueLabel_4Damien Conover, CFA - Sector Director - Morningstar Inc.

Directors' Share Dealings
 Transaction Holding 
Director/Date/TypeAmountPrice (GBX)Value (£) Amount% Additional Info
Dr. Hal V Barron
16/04/2024 | Purchase
5,81219.90115,642.00 648,3990.016 ADRs
Dr. Hal V Barron
16/04/2024 | D
85420.4017,422.00 642,5870.016 ADRs
Ms. Emma N. Walmsley
16/04/2024 | D
1,2791,629.0020,835.00 736,0640.018 Dividend Reinvestment Plan(DRIP)
Ms. Emma N. Walmsley
16/04/2024 | D
1,8411,611.2829,664.00 746,2150.018 Dividend Reinvestment Plan(DRIP)
Ms. Emma N. Walmsley
16/04/2024 | D
7701,629.0012,543.00 734,7850.018 Dividend Reinvestment Plan(DRIP)
Ms. Emma N. Walmsley
16/04/2024 | D
6,8641,629.00111,815.00 744,3740.018 Dividend Reinvestment Plan(DRIP)
Ms. Emma N. Walmsley
16/04/2024 | D
1,4461,629.0023,555.00 737,5100.018 Dividend Reinvestment Plan(DRIP)
Ms. Julie Brown
16/04/2024 | D
5511,629.008,976.00 23,686< 0.001 Dividend Reinvestment Plan(DRIP)
Dr. Hal V Barron
12/04/2024 | Purchase
2620.48532.00 641,7330.016 ADRs
Mr. Charles A. Bancroft
12/04/2024 | Purchase
13620.482,785.00 50,5700.001 ADRs
Dr. Vishal Sikka
12/04/2024 | Purchase
8620.481,761.00 10,506< 0.001 ADRs
Dr. Jesse Goodman, M.D.,M.P.H.
12/04/2024 | Purchase
1820.48369.00 28,696< 0.001 ADRs
Ms. Elizabeth McKee Anderson
12/04/2024 | Purchase
2220.48451.00 2,8180.00 ADRs
Dr. Anne Beal
12/04/2024 | Purchase
1820.48369.00 6,098< 0.001 ADRs
Dr. Harry C Dietz
12/04/2024 | Purchase
1820.48369.00 5,666< 0.001 ADRs
Ms. Emma N. Walmsley
11/04/2024 | D
241,630.94391.00 734,0150.018 Dividend Reinvestment Plan(DRIP)
Ms. Emma N. Walmsley
10/04/2024 | Purchase
81,612.77129.00 733,9830.018 Partnership
Ms. Julie Brown
10/04/2024 | Purchase
71,612.77113.00 23,128< 0.001 Partnership
Dr. Hal V Barron
20/03/2024 | Purchase
43820.959,177.00 641,7070.016 ADRs
Sir Jonathan Richard Symonds CBE
20/03/2024 | Purchase
2,9001,659.8948,137.00 71,1070.002 
Damien Conover, CFA - Sector Director - Morningstar Inc.
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.